Description: <p><b>Bruteridin</b> is a bergamot-derived HMG-bearing flavanone neohesperidoside isolated from <i>Citrus bergamia</i> fruit and best understood as a specialized citrus polyphenol rather than a cardiac glycoside or classic anticancer drug. It is commonly discussed together with the closely related compound melitidin and occurs within <b>bergamot juice</b> or bergamot polyphenolic fractions rather than as a clinically deployed purified agent. Functionally, it is most strongly linked to statin-like HMG-CoA reductase interaction, with broader antioxidant, anti-inflammatory, and metabolic effects generally attributed to bergamot mixtures. No approved oncology use or standard abbreviation is established for purified bruteridin.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>HMG-CoA reductase binding and mevalonate-pathway suppression potential</li>
<li>Polyphenol-associated anti-inflammatory and redox-modulatory activity in bergamot mixtures</li>
<li>Indirect effects on mitochondrial function, autophagy, and metabolic stress pathways when delivered as part of bergamot polyphenolic fractions</li>
<li>Possible anticancer contribution within bergamot extracts, but not yet isolated mechanistically for purified bruteridin</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Dedicated human PK data for purified bruteridin are lacking. After bergamot juice intake, circulating species detected in humans are mainly phase II conjugates of hesperetin, naringenin, and eriodyctiol derivatives, indicating substantial intestinal/hepatic transformation of bergamot flavanones rather than demonstrated sustained intact systemic bruteridin exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most cancer-relevant data come from bergamot juice/extract studies using complex mixtures at mg/mL-range in vitro, which should not be assumed to reflect achievable free systemic concentrations of purified bruteridin. The translational bridge from bergamot mixture exposure to isolated bruteridin anticancer activity remains weak.</p>
<p><b>Clinical evidence status:</b> For cancer, evidence for bruteridin itself is preclinical/inferential only. Human data exist for bergamot extracts in cardiometabolic settings, not for purified bruteridin as an anticancer agent. At present this is best categorized as preclinical and mixture-based, with no oncology RCT or approved therapeutic deployment for the isolated compound.</p>
<h3>Mechanistic relevance table</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>HMG-CoA reductase and mevalonate pathway</td>
<td>↓ mevalonate signaling potential</td>
<td>↓ cholesterol synthesis potential</td>
<td>R-G</td>
<td>Metabolic growth restraint</td>
<td>Best-supported direct mechanism for bruteridin. Evidence is strongest from isolation and computational binding work showing statin-like structural/active-site compatibility, but direct cancer-cell validation for purified bruteridin is limited.</td>
</tr>
<tr>
<td>2</td>
<td>Inflammatory signaling</td>
<td>↓ NF-κB-linked inflammatory tone (context-dependent)</td>
<td>↓ inflammatory stress</td>
<td>G</td>
<td>Microenvironment modulation</td>
<td>Supported mainly at bergamot extract or bergamot polyphenolic fraction level, not cleanly assigned to bruteridin alone.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial stress and autophagy</td>
<td>↔ or ↑ stress susceptibility (context-dependent)</td>
<td>↔ or ↓ injury in non-malignant stress models</td>
<td>G</td>
<td>Metabolic stress remodeling</td>
<td>Bergamot mixtures modulate mitochondrial function and autophagy in hepatic and cardiovascular models. Bruteridin may contribute indirectly, but isolated evidence is insufficient.</td>
</tr>
<tr>
<td>4</td>
<td>ROS balance</td>
<td>↔ (not established for purified bruteridin)</td>
<td>↔ (not established for purified bruteridin)</td>
<td>R-G</td>
<td>Context-dependent redox modulation</td>
<td>CRC studies with bergamot juice extract show ROS increase and apoptosis, but these results cannot be attributed specifically to bruteridin.</td>
</tr>
<tr>
<td>5</td>
<td>Apoptosis and cell-cycle control</td>
<td>↑ apoptosis potential (mixture-level evidence)</td>
<td>↔</td>
<td>G</td>
<td>Antiproliferative pressure</td>
<td>Observed in bergamot juice extract models of colorectal cancer; purified bruteridin-specific evidence is currently absent.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Low direct evidence</td>
<td>Unknown purified-agent safety margin</td>
<td>G</td>
<td>Translation limited by evidence gap</td>
<td>Main constraints are lack of purified-bruteridin oncology studies, uncertain intact oral exposure, reliance on bergamot mixtures, and potential bergamot-associated drug-interaction concerns from co-occurring furanocoumarins in some preparations.</td>
</tr>
</table>
<p>TSF: P: 0–30 min<br>R: 30 min–3 hr<br>G: >3 hr</p>